Since the data of systems pharmacology illustrated that SFH may regulate several key targets and biological processes of sepsis, such as PPARG in inflammatory response, GSK3β and MAPK14 in cell proliferation, and PTGS2 in coagulation, we hypothesized that SFH improves the condition of critically ill COVID-19 patients with septic syndrome by ameliorating lung injury, suppressing excessive inflammation but enhancing the capacity of pathogen phagocytosis and killing, and improving the function of blood coagulation. This evidence concerns the gene MAPK14 and Sepsis.